Why the study?
Does melatonin reduce adriamycin-induced cardiotoxicity and affect its antitumor activity in preclinical models?
Population
Rats and human breast cancer cells
Comparison
Melatonin in combination with adriamycin vs Adriamycin alone
Design
Preclinical
Authors
Loading...
Hypothesis-generating for melatonin as anthracycline adjunct; requires randomized human trials before clinical consideration.
Does melatonin reduce adriamycin-induced cardiotoxicity and affect its antitumor activity in preclinical models?
Melatonin protects against adriamycin-induced cardiotoxicity and enhances its antitumor activity in preclinical models, suggesting a potential protective adjunct therapy.
Kim et al. (2005) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: